quarterly earnings call
The New York-based company also reported a 110% increase in fourth-quarter revenue in 2024 compared to Q4 2023 and a Q4 2024 net loss of $9.6 million.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
DarioHealth also relayed that its revenue increased by 1.7% in the second quarter of the year, compared to the same period last year.
Talkspace also announced a 29% year-over-year revenue growth in the second quarter, and Clover Health reported an 11% increase in revenue.
The company's stock price dropped after it released its first-quarter earnings and lowered its full-year guidance despite an increase in revenue.
Clover Health reports first-time profitability on an adjusted EBITDA basis in the first quarter.
The company notified the SEC of a data breach after discovering an unauthorized party stole consumers' sensitive information, including patient health data.
The quarter marks the first time the company reported profitability on an adjusted EBITDA basis.
The health tech giant reported lower-than-expected sales and profits in the first quarter, resulting in its shares plummeting.
The company's revenue increased in Q2 of this year to $13.1 million compared to $10.7 million in the first quarter – still below the $18.3 million reported in Q2 2022.